1. Home
  2. BGX vs BIOA Comparison

BGX vs BIOA Comparison

Compare BGX & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

HOLD

Current Price

$11.82

Market Cap

151.0M

Sector

Finance

ML Signal

HOLD

Logo BioAge Labs Inc. Common Stock

BIOA

BioAge Labs Inc. Common Stock

HOLD

Current Price

$12.66

Market Cap

175.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGX
BIOA
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.0M
175.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
BGX
BIOA
Price
$11.82
$12.66
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.33
AVG Volume (30 Days)
67.9K
308.1K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
10.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.69
$2.88
52 Week High
$12.44
$13.08

Technical Indicators

Market Signals
Indicator
BGX
BIOA
Relative Strength Index (RSI) 50.31 82.92
Support Level $11.76 $8.46
Resistance Level $11.90 $9.62
Average True Range (ATR) 0.11 0.72
MACD 0.01 0.33
Stochastic Oscillator 65.22 92.49

Price Performance

Historical Comparison
BGX
BIOA

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

About BIOA BioAge Labs Inc. Common Stock

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Share on Social Networks: